Total Payments
$84,155
2024 Payments
$13,312
Companies
67
Transactions
828
Medicare Patients
3,136
Medicare Billing
$417,167
Payment Breakdown by Category
Other$71,486 (84.9%)
Food & Beverage$11,433 (13.6%)
Travel$656.82 (0.8%)
Education$579.27 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,486 | 48 | 84.9% |
| Food and Beverage | $11,433 | 764 | 13.6% |
| Travel and Lodging | $656.82 | 3 | 0.8% |
| Education | $579.27 | 13 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $43,877 | 128 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $24,573 | 35 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $5,055 | 21 | $0 (2022) |
| LivaNova USA, Inc. | $1,013 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $649.88 | 46 | $0 (2024) |
| MDD US Operations, LLC | $570.49 | 21 | $0 (2024) |
| UCB, Inc. | $567.57 | 28 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $545.90 | 80 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $542.69 | 20 | $0 (2024) |
| Allergan, Inc. | $484.89 | 36 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,312 | 188 | ABBVIE INC. ($10,603) |
| 2023 | $26,548 | 162 | ABBVIE INC. ($24,758) |
| 2022 | $15,463 | 107 | ABBVIE INC. ($8,505) |
| 2021 | $23,812 | 54 | Biohaven Pharmaceuticals, Inc. ($23,448) |
| 2020 | $1,318 | 13 | Biohaven Pharmaceuticals, Inc. ($1,125) |
| 2019 | $1,141 | 81 | Allergan Inc. ($136.77) |
| 2018 | $1,327 | 122 | Teva Pharmaceuticals USA, Inc. ($205.62) |
| 2017 | $1,234 | 101 | Allergan Inc. ($207.54) |
All Payment Transactions
828 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Neurology | ||||||
| 12/19/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Neurology | ||||||
| 12/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $2.70 | General |
| Category: PAIN | ||||||
| 12/17/2024 | Aucta Pharmaceuticals, Inc. | Motpoly XR (Drug) | Food and Beverage | In-kind items and services | $9.34 | General |
| Category: Central Nervous System | ||||||
| 12/13/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.49 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Neurology | ||||||
| 12/09/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.10 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Neurology | ||||||
| 12/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: AMANTADINE | ||||||
| 12/04/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: EPILEPSY | ||||||
| 12/04/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $10.62 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/26/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Immunology | ||||||
| 11/25/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: NEUROLOGY | ||||||
| 11/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $5.61 | General |
| Category: PAIN | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $7.44 | General |
| Category: Neurology | ||||||
| 11/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $5.59 | General |
| Category: PAIN | ||||||
| 11/07/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.39 | General |
| Category: Neuroscience | ||||||
| 11/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: AMANTADINE | ||||||
| 10/30/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Genetic Disease | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Neurology | ||||||
| 10/29/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 614 | 9,208 | $309,569 | $108,147 |
| 2022 | 15 | 651 | 6,383 | $251,053 | $86,858 |
| 2021 | 19 | 908 | 6,788 | $348,589 | $118,910 |
| 2020 | 19 | 963 | 7,454 | $296,767 | $103,253 |
Total Patients
3,136
Total Services
29,833
Medicare Billing
$417,167
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 23 | 8,410 | $109,330 | $41,453 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 394 | $95,742 | $30,846 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $26,394 | $9,699 | 36.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 53 | 56 | $14,504 | $5,319 | 36.7% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 15 | 38 | $11,096 | $3,678 | 33.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 12 | 14 | $9,688 | $3,415 | 35.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 22 | 22 | $8,976 | $3,246 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 43 | $7,396 | $2,222 | 30.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $5,473 | $1,793 | 32.8% |
| 20526 | Injection of carpal tunnel | Office | 2023 | 16 | 25 | $7,130 | $1,776 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $4,116 | $1,591 | 38.7% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 11 | 14 | $4,158 | $1,130 | 27.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 17 | 17 | $3,264 | $1,063 | 32.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 14 | 14 | $1,666 | $617.12 | 37.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 33 | 53 | $636.00 | $298.57 | 46.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 13 | 5,600 | $72,800 | $27,300 | 37.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 240 | 320 | $77,704 | $24,527 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 115 | 135 | $23,200 | $7,246 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 46 | 46 | $14,610 | $5,059 | 34.6% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 32 | 33 | $13,440 | $4,669 | 34.7% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 14 | 14 | $11,354 | $4,121 | 36.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 32 | $8,288 | $3,171 | 38.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 11 | 27 | $7,884 | $2,890 | 36.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 27 | 27 | $5,184 | $1,966 | 37.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $4,876 | $1,846 | 37.9% |
About Dr. Alam Khan, MD
Dr. Alam Khan, MD is a Neurology healthcare provider based in London, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629047162.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alam Khan, MD has received a total of $84,155 in payments from pharmaceutical and medical device companies, with $13,312 received in 2024. These payments were reported across 828 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($71,486).
As a Medicare-enrolled provider, Khan has provided services to 3,136 Medicare beneficiaries, totaling 29,833 services with total Medicare billing of $417,167. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location London, KY
- Active Since 03/16/2006
- Last Updated 05/02/2019
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1629047162
Products in Payments
- QULIPTA (Drug) $30,156
- NURTEC ODT (Drug) $29,925
- UBRELVY (Drug) $13,295
- VNS Therapy (Device) $884.46
- BOTOX (Biological) $642.52
- KESIMPTA (Drug) $415.44
- ACTHAR (Biological) $388.24
- Gocovri (Drug) $374.93
- ZEPOSIA (Drug) $369.69
- APTIOM (Drug) $339.26
- ULTOMIRIS (Biological) $318.45
- TYSABRI (Biological) $249.89
- EMGALITY (Drug) $241.98
- GOCOVRI (Drug) $233.44
- VYVGART (Drug) $222.35
- Briviact (Drug) $211.57
- TROKENDI XR (Drug) $211.05
- VALTOCO (Drug) $200.62
- Ponvory (Drug) $195.59
- ACTIVA (Device) $177.30
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.